Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 12/20 | 1.00 |
| ▸ | EGFR | P00533 | 10/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 10/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 10/20 | 1.00 |
| ▸ | STAT5A | P42229 | 1/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 1/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 9/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.79 |
| ▸ | KIT | P10721 | 3/20 | 0.79 |
| ▸ | WEE1 | P30291 | 3/20 | 0.73 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.73 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.73 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.73 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.70 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.70 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.70 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.70 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30257377 | 1.00 | SRC (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL29765306 | 1.00 | SRC (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL29378902 | 1.00 | SRC (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL1334768 | 0.88 | SRC (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL5764062 | 0.88 | FGFR1 (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL5762046 | 0.87 | SRC (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL5764012 | 0.87 | FGFR1 (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL13498143 | 0.86 | FGFR1 (0.83) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL1249524 | 0.85 | FGFR1 (1.00) | SRCFGFR1EGFRPDGFRBPDGFRA | |
| SCHEMBL28558346 | 0.85 | FGFR1 (0.74) | SRCFGFR1EGFRPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149415-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-05-18 | — | — | US | claimed |
| EP-4127722-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Engine Biosciences Pte. Ltd. (SG) | 2023-02-08 | — | — | EP | claimed |
| WO-2021202780-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2021-10-07 | — | — | WO | claimed |
| EP-3386498-A1 | METHOD FOR MODULATING AUTOPHAGY AND APPLICATIONS THEREOF | Jawaharlal Nehru Centre For Advanced Scientific Research (IN) | 2018-10-17 | — | — | EP | claimed |
| WO-2017098467-A1 | METHOD FOR MODULATING AUTOPHAGY AND APPLICATIONS THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2017-06-15 | — | — | WO | claimed |
| EP-2233174-B1 | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection | UNIV EMORY (US) | 2016-07-20 | — | — | EP | claimed |
| US-20110293615-A1 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-12-01 | — | — | US | claimed |
| EP-2233174-A1 | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection | Emory University (US) | 2010-09-29 | — | — | EP | claimed |
| US-20090053236-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-26 | — | — | US | claimed |
| US-20080220497-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS LLC | 2008-09-11 | — | — | US | claimed |
| EP-1949902-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-07-30 | — | — | EP | claimed |
| EP-1907411-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | Deciphera Pharmaceuticals, LLC. (US) | 2008-04-09 | — | — | EP | claimed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | claimed |
| WO-2007008917-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2005065074-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-07-21 | — | — | WO | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2005065074-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | SRC 1968/4885FGFR1 2522/4885EGFR 1496/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | SRC 1968/4885FGFR1 2522/4885EGFR 1496/4885 |
| US-20110293615-A1 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor | KIT, FLT4, KDR | SRC 244/4885FGFR1 393/4885EGFR 268/4885 |
| US-20080220497-A1 | Modulation of protein functionalities | C1QBP, SERPINA6, CD2BP2 | SRC 2604/4885FGFR1 4698/4885EGFR 4097/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | SRC 9/4885FGFR1 118/4885EGFR 125/4885 |
| US-20090053236-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | KIT, FLT4, KDR | SRC 244/4885FGFR1 393/4885EGFR 268/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | SRC 69/4885FGFR1 184/4885EGFR 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.